Actively Recruiting
A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer
Led by baotai Liang · Updated on 2025-11-26
30
Participants Needed
1
Research Sites
129 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Carrying out clinical trials of salbutamol hydrochloride combined with immunotherapy and castration for the treatment of prostate cancer is of great significance. Firstly, it can verify the efficacy and safety of this combination in the treatment of prostate cancer, providing a scientific basis for its clinical application. Secondly, through clinical trials, the mechanism of action of salbutamol hydrochloride combined with immunotherapy can be further studied. Finally, this clinical trial can further expand the treatment strategies for prostate cancer.
CONDITIONS
Official Title
A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older and younger than 85 years
- Failed at least one chemotherapy regimen containing docetaxel and one standard novel endocrine therapy
- Diagnosed with castration-resistant prostate cancer (CRPC) with testosterone level below 50 ng/ml
- Disease progression within 12 weeks before enrollment with rising PSA levels and soft tissue or bone metastases
- Imaging shows bone metastatic disease or measurable non-bone metastatic disease
- Expected survival of at least 3 months
- Voluntarily signed informed consent and can cooperate with treatment and follow-up
You will not qualify if you...
- Severe cardiovascular and cerebrovascular diseases
- Abnormal liver function with total bilirubin less than 1.5 times upper limit and ALT/AST ratio less than 2 times upper limit
- Abnormal kidney function with serum creatinine less than 1.5 mg/dl or creatinine clearance rate at least 60 cc/min
- Allergy to study drugs
- Presence of tumors in other parts of the body
- Abnormal thyroid function with FT4 or TT4 outside normal range
- Cortisol deficiency with serum cortisol below 140 nmol/L at 8 a.m.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongda Hospital
Nanjing, China
Actively Recruiting
Research Team
B
baotai liang 梁
CONTACT
B
baotai liang 许
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here